On May 20, 2024 Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, reported it will be hosting a webcasted R&D breakfast panel featuring prominent scientific and medical thought leaders to discuss topline overall survival data from its phase 2 clinical trial of CAN-2409, its multimodal biological immunotherapy candidate, in Non-Small Cell Lung Cancer (NSCLC) (Press release, Candel Therapeutics, MAY 20, 2024, View Source [SID1234643466]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will be held on Monday, June 3, 2024, at 7:00 AM Central Time, during the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago.
Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel, will be hosting the event and moderating the guest panel, which includes:
Charu Aggarwal, MD, MPH, FASCO
Leslie M. Heisler Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania
Roy S. Herbst, MD, PhD
Chief of Medical Oncology
Yale School of Medicine
Candel Research Advisory Board
Daniel H. Sterman, MD, FCCP, ATSF, DAABIP
Professor and Director, Pulmonary, Critical Care and Sleep Medicine
NYU Langone Health
A live webcast will be available by selecting Events and Presentations, under the News & Events tab, in the Investors section on Candeltx.com. A replay of the webcast will be archived for up to 90 days following the session date.
EDITOR’S NOTE: Media representatives interested in attending the event should please contact Kyle Evans at [email protected].